Active Ingredient History
Omega-3-acid ethyl esters are a mixture of ethyl eicosapentaenoic acid and ethyl docosahexaenoic acid, which are ethyl esters of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in fish oil. Together with dietary changes, they are used to treat high blood triglycerides which may reduce the risk of pancreatitis. They are generally less preferred than statins, and use is not recommended by NHS Scotland as the evidence does not support a decreased risk of heart disease. Omega-3-acid ethyl esters are taken by mouth. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Accidents (Phase 4)
Affective Symptoms (Phase 3)
Anemia, Sickle Cell (Phase 3)
Anosmia (Phase 2)
Antisocial Personality Disorder (Phase 2/Phase 3)
Aortic Aneurysm, Abdominal (Phase 2)
Arterial Occlusive Diseases (Phase 3)
Autism Spectrum Disorder (Phase 4)
Autistic Disorder (Phase 4)
Bariatric Surgery (Phase 1)
beta-Thalassemia (Phase 2/Phase 3)
Biological Availability (Phase 4)
Blister (Early Phase 1)
Brain Concussion (Phase 2)
Brain Diseases (Phase 2)
Brain Injuries (Phase 4)
Brain Ischemia (Phase 4)
Breast Neoplasms (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Central Nervous System Diseases (Phase 2)
Chronic Pain (Phase 2)
Cognition Disorders (Phase 2)
Cognitive Dysfunction (Phase 3)
Colorectal Neoplasms (Phase 2)
Contact Lenses (Phase 4)
Corneal Diseases (Phase 4)
COVID-19 (Phase 3)
Crohn Disease (Phase 4)
Dementia (Phase 2)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 2/Phase 3)
Diabetic Retinopathy (Phase 4)
Diaphragm (Phase 2)
Dietary Supplements (Phase 4)
Dry Eye Syndromes (Phase 4)
Exercise (Phase 3)
Fatty Liver (Early Phase 1)
Heart Failure (Phase 1/Phase 2)
Hypercholesterolemia (Phase 3)
Hyperlipidemias (Phase 4)
Hypertension, Pulmonary (Phase 2)
Hypertriglyceridemia (Phase 3)
Hypoglycemia (Phase 1/Phase 2)
Inflammation (Phase 4)
Intestinal Neoplasms (Phase 2)
Iron Overload (Phase 2/Phase 3)
Ischemic Stroke (Phase 4)
Learning Disabilities (Phase 4)
Liver Transplantation (Phase 2)
Lung Neoplasms (Phase 2)
Macular Edema (Phase 4)
Mastodynia (Phase 4)
Mental Disorders (Phase 2)
Mood Disorders (Phase 4)
Nervous System Diseases (Phase 4)
Neurocognitive Disorders (Phase 2)
Neurologic Manifestations (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 2)
Olfaction Disorders (Phase 2)
Ovarian Neoplasms (Phase 1/Phase 2)
Oxidative Stress (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 1/Phase 2)
Pathologic Processes (Phase 2)
Peripheral Arterial Disease (Phase 2)
Primary Immunodeficiency Diseases (Phase 3)
Renal Insufficiency, Chronic (Phase 3)
Schizophrenia (Phase 2)
Severe Acute Malnutrition (Phase 3)
Sjogren's Syndrome (Phase 2/Phase 3)
Stroke (Phase 4)
Urological Manifestations (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
